Deals in Depth: September 2008
September 2008 dealmaking highlights: Medivation landed a potential $725mm through its deal with Pfizer for AD/Huntington's candidate Dimebon. In top M&As, Japanese firm Shionogi acquired US-based Sciele for $1.4bn and Getinge paid $841mm for fellow CV-focused Datascope. Compared with September, FOPO money into biopharma almost doubled thanks to Vertex's $218mm offering, while on the device side no follow-ons were completed and private financing decreased about $100mm.
You may also be interested in...
The US FDA released five device-related close-out letters in March.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.